drugset
drugset / Trial / NCT05206201

A Study Of Zy-19489 Administered Via Oral Route To Investigate The Safety, Tolerability And Pharmacokinetics In Healthy Adult Human Subjects

NCT05206201 ↗

Phase 1 Completed 24 enrolled Zydus Lifesciences Limited
RandomizedParallel-groupDouble-blindTreatment

Summary

A Randomized, Double Blind, Parallel, Placebo-Control, Study Of ZY-19489 Administered Via Oral Route To Investigate The Safety, Tolerability And Pharmacokinetics In Healthy Adult Human Subjects aged between 18-55 years old (Both Inclusive).

Timeline

Start
2021-08-25
Primary completion
2022-01-21
Completion
2022-01-21

Drugs

EvaluationDrugModalityDoseRoute
Subject SUTIDIAZINE Small molecule — Oral

Indications

malaria